Interestingly, the in vitro increase in tumour cell migration and invasion in Bev-A cells was abrogated by VEGFR1 inhibition, suggesting that perhaps this combination should be further explored in preclinical studies and, if appropriate, in clinical studies. Here, FLT1 is linked to neoplasm.